5.92 USD
-0.06 (-1%)
5.97 USD
+0.05 (+0.84%)
We assign a fundamental rating of 3 out of 10 to NEOG. NEOG was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
NEOG had positive earnings in the past year.
NEOG had a positive operating cash flow in the past year.
In multiple years NEOG reported negative net income over the last 5 years.
In the past 5 years NEOG always reported a positive cash flow from operatings.
1.2 Ratios
NEOG has a Return On Assets (-30.88%) which is comparable to the rest of the industry.
NEOG has a Return On Equity (-49.23%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NEOG (46.39%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NEOG has remained more or less at the same level.
NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEOG has about the same amount of shares outstanding.
Compared to 5 years ago, NEOG has more shares outstanding
NEOG has a worse debt/assets ratio than last year.
2.2 Solvency
NEOG has an Altman-Z score of 0.78. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
NEOG has a Altman-Z score (0.78) which is comparable to the rest of the industry.
NEOG has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
NEOG has a Debt to Equity ratio of 0.37. This is comparable to the rest of the industry: NEOG outperforms 47.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.78 |
ROIC/WACCN/A
WACC7.59%
2.3 Liquidity
NEOG has a Current Ratio of 3.58. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NEOG (3.58) is better than 64.89% of its industry peers.
A Quick Ratio of 2.26 indicates that NEOG has no problem at all paying its short term obligations.
NEOG has a Quick ratio (2.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The earnings per share for NEOG have decreased strongly by -25.00% in the last year.
The earnings per share for NEOG have been decreasing by -10.20% on average. This is quite bad
NEOG shows a decrease in Revenue. In the last year, the revenue decreased by -2.77%.
NEOG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.43% yearly.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
3.2 Future
NEOG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.29% yearly.
The Revenue is expected to grow by 0.76% on average over the next years.
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.73, the valuation of NEOG can be described as rather expensive.
81.38% of the companies in the same industry are more expensive than NEOG, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of NEOG to the average of the S&P500 Index (26.11), we can say NEOG is valued slightly cheaper.
The Price/Forward Earnings ratio is 17.07, which indicates a rather expensive current valuation of NEOG.
82.98% of the companies in the same industry are more expensive than NEOG, based on the Price/Forward Earnings ratio.
NEOG is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.73 | ||
| Fwd PE | 17.07 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NEOG is valued a bit cheaper than the industry average as 76.06% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.65 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.51%
EPS Next 3Y6.43%
5. Dividend
5.1 Amount
NEOG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.92
-0.06 (-1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.45%
Inst Owner Change2.38%
Ins Owners0.42%
Ins Owner Change84.05%
Market Cap1.29B
Revenue(TTM)886.89M
Net Income(TTM)-1.04B
Analysts76.36
Price Target7.78 (31.42%)
Short Float %10.75%
Short Ratio4.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)15.53%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)2
Avg EPS beat(8)-1.35%
EPS beat(12)4
Avg EPS beat(12)52.58%
EPS beat(16)5
Avg EPS beat(16)29.73%
Revenue beat(2)1
Avg Revenue beat(2)0.03%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)0.46%
Revenue beat(8)2
Avg Revenue beat(8)-0.99%
Revenue beat(12)3
Avg Revenue beat(12)-0.84%
Revenue beat(16)3
Avg Revenue beat(16)-1.21%
PT rev (1m)17.31%
PT rev (3m)17.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)77.78%
EPS NY rev (3m)-2.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.73 | ||
| Fwd PE | 17.07 | ||
| P/S | 1.45 | ||
| P/FCF | N/A | ||
| P/OCF | 14.78 | ||
| P/B | 0.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | 19.65 |
EPS(TTM)0.3
EY5.07%
EPS(NY)0.35
Fwd EY5.86%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.4
OCFY6.76%
SpS4.08
BVpS9.75
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.03 | ||
| Cap/Depr | 75.94% | ||
| Cap/Sales | 10.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 88.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 0.78 |
F-Score3
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
EBIT growth 1Y-147.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.85%
EBIT Next 3Y34.71%
EBIT Next 5Y20.44%
FCF growth 1Y39.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.3%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
Can you provide the valuation status for NEOGEN CORP?
ChartMill assigns a valuation rating of 4 / 10 to NEOGEN CORP (NEOG). This can be considered as Fairly Valued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 3 / 10.
What is the earnings growth outlook for NEOGEN CORP?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -25.82% in the next year.